Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -72.95% | -68.75% | -76.03% | 85.04% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -72.95% | -68.75% | -76.03% | 85.04% | -- |
| Cost of Revenue | -134.60% | -136.40% | -138.81% | 85.64% | -- |
| Gross Profit | -50.33% | -40.31% | -50.70% | 84.88% | -- |
| SG&A Expenses | 46.94% | 83.52% | 27.84% | 1.39% | -- |
| Depreciation & Amortization | 76.79% | 63.40% | 50.00% | 31.63% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.72% | 33.70% | 3.07% | 29.35% | -- |
| Operating Income | -327.43% | -400.43% | -541.36% | 15.00% | -- |
| Income Before Tax | -188.86% | -207.82% | -191.27% | -4.94% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -188.86% | -207.82% | -191.27% | -4.94% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -188.86% | -207.82% | -191.27% | -4.94% | -- |
| EBIT | -327.43% | -400.43% | -541.36% | 15.00% | -- |
| EBITDA | -369.84% | -459.59% | -693.89% | 17.79% | -- |
| EPS Basic | -159.65% | -177.36% | -175.00% | 1.45% | -- |
| Normalized Basic EPS | -160.00% | -172.73% | -168.00% | 2.33% | -- |
| EPS Diluted | -159.65% | -177.36% | -175.00% | 1.45% | -- |
| Normalized Diluted EPS | -160.00% | -172.73% | -168.00% | 2.33% | -- |
| Average Basic Shares Outstanding | 10.16% | 7.45% | 4.33% | 4.79% | -- |
| Average Diluted Shares Outstanding | 9.56% | 6.85% | 3.74% | 5.36% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |